BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched a new treatment for gastroesophageal reflux disease under a partnership with a South Korean drug maker.
Amneal announced Tuesday the launch of esomeprazole strontium delayed-release capsules in the 49.3-mg strength, which it is marketing in the United States under a contract with Hanmi Pharmaceutical Co. The drug is expected to begin shipping Wednesday in 30-count bottles.
The drug is being marketed as an alternative to AstraZeneca's Nexium (esomeprazole magnesium), though it received approval from the Food and Drug Administration in August as a branded drug. The drug contains a similar active ingredient to Nexium, but in a different salt form.